The expansion marks the first therapy approved for patients with BCG-unresponsive non-muscle-invasive bladder cancer presenting with papillary-only disease.

(HealthDay News) — Among patients with cancer with a genetic variant that increases the risk for hereditary cancers, personalized support significantly increases the likelihood that their first-degree ...

(HealthDay News) — Less than 30 percent of women with estrogen receptor (ER)-positive early-stage breast cancer (ESBC) treated with lumpectomy remain adherent to endocrine therapy (ET) at five years, ...

Researchers conducted a systematic case review to characterize the clinical presentation and underlying malignancies associated with Bazex syndrome.

In a new study, patients with intestinal inflammatory disease who received immune checkpoint inhibitor (ICI) therapy appeared to have increased risk of ...

A randomized phase 2 trial evaluated whether prophylactic goshajinkigan reduces the incidence of CIPN in patients receiving carboplatin plus paclitaxel.

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

Psychotherapy within one week of cancer diagnosis linked to 27 percent lower risk for cancer-specific mortality ...

Most women aware of modifiable behaviors to lower breast cancer risk, yet there is a gap between awareness and adoption of risk-cutting behaviors ...